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and promote services and/or treatments. This study can also help to assess the cost-
beneﬁt ratio of folic acid supplementation and the cost-beneﬁt ratio of recommended 
food supplements.
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OBJECTIVES: Fibromyalgia or ﬁbromyalgia syndrome (FMS) is characterized by 
chronic widespread muscular pain and generalized tender points, often accompanied 
by a number of associated symptoms such as fatigue, sleep disturbance, psychological 
distress. The objective of this study was to assess the medical resource utilization 
(MRU) and workdays lost (WDL) of FMS patients according to the level of pain and 
fatigue. METHODS: The Adelphi Fibromyalgia Disease Speciﬁc Programme is a cross-
sectional survey among 2159 FMS patients in France, Germany, Italy, Spain and the 
UK. The survey included one questionnaire ﬁlled in by the patient and one by the 
physician. Patient health states were deﬁned on the basis of items 15 and 16 (100 mm 
VAS scales) of FIQ (Fibromyalgia Impact Questionnaire). RESULTS: From the pool 
of 2159 FMS patients, most patients with moderate pain (80.5%) or severe pain 
(95.5%) also suffered from fatigue. A total of 1341 patients had signiﬁcant fatigue 
(cut off: 50 mm), associated with mild (40 mm; N  154), moderate (40–70 mm; N 
 587) or severe (70 mm; N  600) pain. The annual number of physician visits per 
patient (5.71, 6.14 and 7.47 respectively), co-medication costs per 4 weeks (£3.66, 
£5.48 and £8.11), as well as the annual hospitalisation rate (2.6%, 5.6% and 7.5%) 
and length of stay per patient per year (0.42, 1.69 and 1.95 days, respectively) 
increased following the level of pain. Similarly, the percentage of patients on sick leave 
and its duration were larger in patients with fatigue and moderate (11.9% and 40 
weeks) or severe (20.0% and 44 weeks) pain, compared to patients with mild pain 
(8.4% and 33 weeks). CONCLUSIONS: In patients with FMS who present with sig-
niﬁcant fatigue, medical resource utilization and workdays lost are driven by the level 
of pain.
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OBJECTIVES: This review was performed to document and analyse the evolution of 
costs in Fibromyalgia (FM). METHODS: A systematic review (SR) was performed 
using Mesh terms (Medline 1980–2009). Articles on FM were selected if they pre-
sented direct or indirect costs. Two researchers extracted costs which were divided by 
type of resource. Total direct costs were divided by health care visits, hospitalization, 
procedures and drug costs; and, indirect costs in two types: absenteeism or work with 
reduced productivity. Costs were compared and differences were documented. Trends 
analysis was performed after converting results to USD$. RESULTS: Out of 28 cita-
tions, 7 articles were included. Four papers reported costs in USD$, 2 in Euros and 1 
in CA$. Costs were reported /patient/year, except for the Canadian 6-month study. 
All studies identiﬁed total direct costs, disaggregated in subtypes by 6 of them. Five 
studies reported total indirect costs; 3/5 reported on absenteeism and on reduced 
productivity. Three US studies were performed before 2000, and one in 2005. There 
was a progression in total direct costs/patient/yr from 1996 to 2005 from USD$2274 
to USD$7286 respectively and for total indirect costs, from USD$1010 to USD$2913. 
Two European analyses provided similar total direct costs/patient/yr, but did not 
report on the same indirect costs. The 6-month results were excluded from the primary 
trend analysis. A slope of y  1990x and R2  0.83 was obtained, showing a reliable 
increasing trend. Including the 6-month analysis (multiplied by 2), results changed to 
y  1881x, R2  0.64. CONCLUSIONS: This SR and trend analysis documented two 
major categories and subtypes of costs reported for FM, and detected an increasing 
trend. Limitations arose from adjusting indirect costs in two studies and the inclusion 
of papers from various settings. Further detailed analyses, including costs of comor-
bidities and premature death, are warranted to establish the full economic impact of 
FM.
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OBJECTIVES: The purpose of this analysis was to assess the direct and indirect costs 
of rheumatoid arthritis (RA) treatment in Poland in the years 2003–2007. METHODS: 
In order to estimate the direct medical costs of RA, including the costs of medical 
consultation, hospitalization, rehabilitation, drugs and diagnostic tests, data for the 
years 2004–2007 of the National Health Fund were used. Indirect costs like costs of 
pensions for incapacity for work, the costs of rehabilitation and social costs of rents 
for the years 2003–2007 were obtained from the Department of Social Security. 
RESULTS: Direct medical costs of RA in Poland ranged from 115.7 million pln in 
2004 to 126.5 million pln in 2007. Costs of hospital treatment amounted up to 70% 
of the direct costs in 2007. Indirect costs amounted to almost 60 million pln in 2003 
and rose to over 62 million pln in 2007. The largest share of these costs constitute 
the costs of pensions for incapacity for work, which share in indirect costs was 83% 
in 2007. Costs of rehabilitation were increasing in subsequent years (from around 4 
million in 2003 to 9.7 million pln in 2007). The total cost of treatment of RA showed 
an upward trend, reaching a value almost 177 million pln in 2004 and increased to 
almost 188 million pln in 2007. The total cost was dominated by the direct costs with 
share equal to 65% in 2004 to 66.8% in 2007 of the total costs. CONCLUSIONS: 
From year to year RA causes a growing economic burden on the health care and social 
insurance in Poland. The cost structure is dominated by the direct costs, which in turn 
largely consist of the costs of hospital treatment. Indirect costs are affected largely by 
rents due to the inability to work.
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OBJECTIVES: To estimate the costs savings in outpatient medical resource use associ-
ated with diagnosing ﬁbromyalgia during the four years after diagnosis in ﬁve European 
countries (UK, France, Italy, Spain, Germany). METHODS: The UK resource use data 
were extracted from medical records of 2,260 patients diagnosed with FM between 
1998 and 2003 in the General Practice Research Database (GPRD). For the others 
countries, a questionnaire was created based on the UK data and local experts, GP 
and rheumatologists, were asked to compare their own clinical practice to UK prescrip-
tions in terms of tests, drugs, general practitioners and specialists visits, over a period 
of 4 years before diagnosis to 4 years after the diagnosis. Medical resource use if 
diagnosis would not have been established was predicted using adapted published 
Poisson loglinear regression models. The observed and predicted trends in outpatient 
resource use and costs were calculated, so the impact of diagnosis could be evaluated 
for each of these medical resources. RESULTS: In the ﬁve countries studied, whereas 
costs are increasing during the years till diagnosis (40–72% in 4 years, a394a per 
patient the year of diagnosis from the health care perspective in Italy to a2108 in 
Germany), after diagnosis a decrease is observed (5–10%). Compared to a diagnosed 
FM patient, a non-diagnosed patient represents an incremental cost that ranges 
between 97a (Italy) and a421a (Spain) per patient and per year from the health care 
payer perspective. These higher costs are due to more GP and specialist visits and 
diagnostic tests. An earlier diagnosis allows from the societal perspective savings ranged 
from 106a (Italy) to a432 (Spain) per patient and per year. CONCLUSIONS: Making 
the diagnosis of FM reduces costs gradually independent of the country studied.
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OBJECTIVES: To compare the resource use and related costs associated with the 
management of ﬁbromyalgia (FM) in ﬁve European countries (UK, France, Italy, 
Spain, Germany). METHODS: The UK resource use data were extracted from medical 
records of 2,260 patients diagnosed with FM between 1998 and 2003 in the General 
Practice Research Database (GPRD). For the other countries, a questionnaire was 
created based on the UK data and local experts, GP and rheumatologists, were asked 
to compare their own clinical practice to UK prescriptions in terms of tests, drugs, 
general practitioners and specialists visits, over a period of 4 years before diagnosis 
to 4 years after the diagnosis. Information on paramedical and alternative care was 
also collected for France, Italy, Spain, Germany. Inpatient care and productivity loss 
were not included in GPRD and thus also not in the questionnaire. The public payer 
and societal perspective were used. RESULTS: Resource use and average costs related 
to lab tests per person-year from the public health care payer perspective were highest 
in Spain (101a) and the UK, the year of diagnosis and decrease afterwards (a69 in 
Spain). Drug costs are higher in Germany (a242a) mainly due to the higher unit costs. 
Costs related to GP visits increase till diagnosis in Germany (a892) and the UK. The 
costs for referrals to specialists are the highest before diagnosis in the UK (a131), 
France, and Italy. Overall, the highest mean annual total cost per patient from the 
societal perspective was found in Germany (a1,897), the lowest in Italy (a454). The 
highest patient contribution was seen in France (54%), the lowest in Italy (16%). 
CONCLUSIONS: Although moderate differences between countries were found in the 
management of FM, once a formal FM diagnosis was made, the resource use and costs 
decreased independent of the countries studied.
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OBJECTIVES: Balloon kyphoplasty (BKP) is a minimally invasive procedure for the 
treatment of painful vertebral compression fractures (VCFs). Superior clinical out-
comes data versus non surgical management (NSM) has recently been demonstrated 
in a large RCT comparing BKP and VCF. Furthermore, preliminary results of a large 
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retrospective US medicare claim base data analysis have been shown to signiﬁcantly 
decrease mortality risk of a VCF patient when treated with BKP compared to NSM. 
Aim of this study is the evaluation of resource usage and costs for treatment of BKP 
patients in comparison to NSM patients from a social insurance perspective. 
METHODS: In this prospective, non-randomised follow-up-study treatment and costs 
were evaluated in 8 study centers in Germany between 2005 and 2008. Data was 
recorded by questionnaires at baseline and by phone at follow-up. Resource usage 
was valued by DRG for inpatient treatment, EBM fur outpatient treatment and 
Lauer-taxe for medication. RESULTS: The higher initial DRG treatment costs in the 
BKP arm are partially off-set by lower follow-up costs (Follow-up DRG costs: BKP: 
a131.08; NSM: a1149.75; Mann-Whitney-U: p  0.006; Outpatient treatment: BKP: 
a860.57; NSM: a991.65; Mann-Whitney-U: p  0,300; Medication: BKP: a136.56; 
NSM: a338.42; Mann-Whitney-U: p  0.007). Total costs for the BKP patients were 
a 3,874.12 higher than for the NSM patients (Mann-Whitney-U: p  0.000). Compared 
to NSM, BKP treated patients had signiﬁcantly shorter hospital stay for both the initial 
and follow-up hospitalization (9.6 versus 14.7, p  0.000 and in follow-up hospitaliza-
tion 10.7 versus 17.7, p  0.005). CONCLUSIONS: The higher baseline costs of BKP 
versus NSM are partially off-set by reduced follow-up treatment costs. The remaining 
additional costs have to be weighted against shorter hospital stay and improved clinical 
outcomes. Full economic evaluations of BKP versus NSM in the UK, Italy and Spain 
have already demonstrated the cost-effectiveness of BKP versus NSM.
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OBJECTIVES: TNF-A inhibitors are becoming a widely used treatment option for 
rheumatoid arthritis (RA) in the South African private sector. Justiﬁcation for reim-
bursement decisions range from pure list price comparisons to cost of treatment com-
parisons, with limited use of health economics, since South African private health care 
funders have a developing understanding of health economics. The objective of this 
cost of treatment comparison is to estimate the total direct medical costs associated 
with the use of TNF-A inhibitors for the treatment of RA in the South African private 
sector. METHODS: This analysis compares the cost of treatment using the results of 
the DART dose escalation study comparing etanercept, adalimumab and inﬂiximab. 
The expected direct medical costs were estimated over a one year period under two 
scenarios (dose escalation and no dose escalation) and included the costs of TNF-A 
inhibitors, administration, consultation and dispensing. The scenario excluding dose 
escalation was based on minimum label dose and the dose escalation scenario was 
based on 12 months of actual dosing of each TNF-A inhibitor from the DART data. 
Cost values were estimated from the perspective of the South African private health 
care funder. RESULTS: Total direct medical costs associated with the use of etaner-
cept, adalimumab and inﬂiximab are respectively R118,235, R118,357 and R121,481 
per person based on the DART dose escalation study. The cost associated with adali-
mumab is 5% lower compared with etanercept and inﬂiximab when the effect of dose 
escalation is not taken into account. The total cost of treatment for the total popula-
tion of private sector RA patients using TNF-A inhibitors is 77 million ZAR (a6.9 
million). CONCLUSIONS: The direct medical costs associated with the use of TNF-A 
inhibitors for the treatment of RA patients in South Africa are similar despite the dif-
ferences in list prices of these agents.
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OBJECTIVES: To establish the total direct medical cost of patients in second-line TNF 
a therapy from the French heath care system perspective. METHODS: A multicentre 
observational study was conducted, recruiting patients treated since at least four 
months by a second TNF a therapy. The sample represented was assessed through the 
comparison of the regional allocation of inclusions to the regional allocation of TNF 
a prescriptions issued from a national panel. Inpatient and outpatient consumptions 
were collected retrospectively, for the preceding four months. Respect of clinical 
practice recommendations was assessed through the analysis of administration fre-
quencies and posologies. RESULTS: Fifty-nine hospital centres participated in the 
study, including 277 patients. The sample could be considered as representative as 
the correlation between the regional activity in terms of TNF a prescriptions and the 
number of included patients per region was high (r  0.88). The resulting total annual 
direct medical cost equalled a16,000 per patient. Respectively 43, 132, and 102 
patients were included in the INF, ETA and ADA groups. Two patients treated 
by INF received more than the expected number of administrations, whereas 8 others 
had a higher dosage than that recommended. Respectively 11.4% and 24.5% of 
patients treated by ETA and ADA also received more administrations than expected 
during the 4 months of treatment. CONCLUSIONS: This representative study 
stated that hospitalisation costs represented 92% of the total direct medical costs of 
patients treated by a second-line TNF a therapy, reaching a16,000 per patient and 
per year. In the absence of a speciﬁc market authorisation in the indication, TNF a 
therapies are prescribed, but the clinical practice recommendations are not always 
respected.
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OBJECTIVES: to examine the cost-beneﬁt of management strategies for reducing road 
trafﬁc injuries. METHODS: The study was a cross-sectional analysis of secondary 
data retrieved from the Injury Surveillance (IS) in the ﬁscal year 2004 to 2006. The 
sample consisted of all trafﬁc accidental patients who received hospital emergency 
services. The two dependent variables used were direct medical cost and death, mul-
tiple linear regression models and binary logistic regression models were constructed. 
The outputs of management strategies: non-use of crash helmets and drunk driving 
were explained by using Monte Carlo technique. RESULTS: The study covered 12,651 
patients. For the regression analysis, statistically signiﬁcant predictors were composed 
of sex, age, drunk driving, non-use of crash helmets, accidental timing, victim and 
severity (adjusted R2  0.60). For the binary logistic regression analysis, odd-ratio of 
the causes of death of non-use of safety equipments (helmet and seatbelt) and drunk 
driving were 3.56 (CI 2.62–4.85) and 1.24 (CI 1.01–1.53) respectively. The direct 
medical cost arrived at from using the regression model when using law enforcement 
with 50 percent succession of both strategies was THB20,983,413.59. Compare with 
the current situation, it was THB26,709,449.76 (21.44% save). In the same way, the 
net beneﬁt gain from these enforcement was THB512,894,977.48. (58.44% save). 
Nevertheless, changing each assumption of the successful management strategies from 
10% to 50%, the sensitivity analysis shows the range of saving from 24.67% to 
58.44% and the beneﬁt to cost ratio was 10.81. CONCLUSIONS: These ﬁndings 
show the scenario to reduce trafﬁc injury, the law enforcement strategies for using 
safety equipment and reduce the number drunk driving is a useful management tool 
to reduce cost of illness nearly three-quarters of the damages from road trafﬁc 
injuries.
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OBJECTIVES: Biologic agents are commonly used sequentially to treat moderate to 
severe rheumatoid arthritis (RA). In absence of clinical trials comparing biologic 
strategies, simulation models are useful to inform decisions. The objective is to 
assess, using the NHS perspective, the cost-effectiveness of biologic strategies in 
patients with an insufﬁcient response (IR) to at least 1 anti-TNF agent. METHODS: 
Simulation models were developed to assess four strategies of different biologic agents 
over 2 years. Assuming an IR to the 1st anti-TNF agent, Sequence 1 included etaner-
cept-abatacept-adalimumab and Sequence 2 etanercept-rituximab-adalimumab. 
Assuming an IR to 2 anti-TNF agents, Sequence 3 included etanercept-adalimumab-
abatacept and Sequence 4 etanercept-adalimumab-inﬂiximab. Effectiveness data was 
derived from published evidence based on achieving a low disease activity state 
(LDAS). Switch occurred at each 6 months in case of an IR to the previous agent. 
UK direct medical costs and biologic drug costs were used. Extensive probabilistic 
sensitivity analyses were performed. RESULTS: There were 6-month medical costs 
(excluding biologic drug costs) were estimated at £1047 (Standard Deviation [SD] 
332) for managing patients in LDAS and at £2650 (SD 963) for moderate-to-high 
disease activity. Over 2 years, Sequence 1 appeared more efﬁcacious (92 days in LDAS) 
versus Sequence 2 (82 days in LDAS,) with cost-effectiveness ratios of £281/day in 
LDAS vs. £289/day in LDAS, respectively. Sequence 3 appeared more efﬁcacious (43 
days in LDAS or) vs. Sequence 4 (32 days in LDAS), with cost-effectiveness ratios of 
£603/day in LDAS vs. £809/day in LDAS, respectively. CONCLUSIONS: Medical 
costs associated with moderate-to-high disease activity are estimated to be 2.5 times 
higher than for LDAS, suggesting that efﬁcacious treatment strategies contribute to 
reducing use of health care services. The results of this simulation model suggest that, 
for achieving LDAS, sequences including abatacept after an IR to at least 1 anti-TNF 
agent appear more cost-effective than similar sequences including rtx or cycled anti-
TNF agents.
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OBJECTIVES: Several studies have demonstrated that compliant and long-term use 
of bisphosphonates is necessary to realize full beneﬁts of treatment. In particular, a 
progressive relation between compliance (medication possession ratio above 80%) and 
fracture risk reduction has been found (Siris, Mayo Clin Proc 2006;81:1013–22 and 
Penning, Osteoporos Int 2008;19:511–17). Taking into account patient compliance, 
we compared the effectiveness and costs of zoledronic acid (ZOL) versus weekly 
alendronate & risedronate and monthly ibandronate therapies over 3 years in the 
prevention of postmenopausal osteoporotic fractures from the NHS perspective of 
Turkey, using Number Needed to Treat (NNT) approach. METHODS: NNT values 
